Evidence map›Paper›PMID 23316252›Full record

ReviewClinical & developmental immunology2012

New platform technology for comprehensive serological diagnostics of autoimmune diseases.

Annika Willitzki, Rico Hiemann, Vanessa Peters, Ulrich Sack, Peter Schierack, Stefan Rödiger, Ursula Anderer, Karsten Conrad, Dimitrios P Bogdanos, Dirk Reinhold and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Investigation of CommensalMicroorganisms · 2021
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Label-free detection of immune complexes with myeloid cells.Clinical and experimental immunology · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Annika WillitzkiInstitute of Molecular and Clinical Immunology, Otto-von-Guericke University, 39120 Magdeburg, Germany.
Rico Hiemann
Vanessa Peters
Ulrich Sack
Peter Schierack
Stefan Rödiger
Ursula Anderer
Karsten Conrad
Dimitrios P Bogdanos
Dirk Reinhold
Dirk Roggenbuck
Frankfurt University of Applied Sciences · DEMedipan (Germany) · DEOtto-von-Guericke University Magdeburg · DEKing's College London · GBLeipzig University · DETU Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody assessment is an essential part in the serological diagnosis of autoimmune diseases. However, different diagnostic strategies have been proposed for the work up of sera in particular from patients with systemic autoimmune rheumatic disease (SARD). In general, screening for SARD-associated antibodies by indirect immunofluorescence (IIF) is followed by confirmatory testing covering different assay techniques. Due to lacking automation, standardization, modern data management, and human bias in IIF screening, this two-stage approach has recently been challenged by multiplex techniques particularly in laboratories with high workload. However, detection of antinuclear antibodies by IIF is still recommended to be the gold standard method for antibody screening in sera from patients with suspected SARD. To address the limitations of IIF and to meet the demand for cost-efficient autoantibody screening, automated IIF methods employing novel pattern recognition algorithms for image analysis have been introduced recently. In this respect, the AKLIDES technology has been the first commercially available platform for automated interpretation of cell-based IIF testing and provides multiplexing by addressable microbead immunoassays for confirmatory testing. This paper gives an overview of recently published studies demonstrating the advantages of this new technology for SARD serology.

Indexed as

AutoantibodiesAutoimmune DiseasesFluorescent Antibody Technique, IndirectHumansSerologic TestsAutoantibodies

Identifiers

PMID23316252
PMCPMC3536031
OpenAlexW2149145393

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.